Gastroduodenal defense

Current Opinion in Gastroenterology

Volumn 23, Issue 6, 2007, Pages 607-616

  Ham, Maggie ^e   Kaunitz, Jonathan D ^a,b,c,d,f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Digestive Disease Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Department of Medicine ^*  (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Brentwood Biomedical Research Institute Los Angeles   (United States)

Author keywords

Cyclooxygenase; Defense; Duodenum; Esophagus; Glucocorticoid; Injury

Indexed keywords

4 BROMOPHENACYL BROMIDE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ATB 337; BICARBONATE; BILE SALT; CS 706; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; DICLOFENAC; ENZYME INHIBITOR; GLUCOCORTICOID; HYDROGEN SULFIDE; IBUPROFEN; INDOMETACIN; MELATONIN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; ROFECOXIB; SEROTONIN; STEROID; TRANSFORMING GROWTH FACTOR ALPHA; TREFOIL PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIOXIDANT ACTIVITY; DIGESTIVE SYSTEM INJURY; DRUG MECHANISM; DRUG MEGADOSE; DUODENUM; DUODENUM MUCOSA; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; HUMAN; LOW DRUG DOSE; MUCUS SECRETION; NONHUMAN; REVIEW; SEX DIFFERENCE; STOMACH; STOMACH INJURY; STOMACH MUCOSA INJURY; ULCER HEALING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DUODENUM; GASTRIC MUCOSA; GLUCOCORTICOIDS; HUMANS; INTESTINAL MUCOSA; MELATONIN; OXIDATION-REDUCTION; PEPTIDES; PHOSPHOLIPIDS; PYRROLES; SEROTONIN; SULFONAMIDES; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 34848922433     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3282f02607     Document Type: Review

References (70)

1. Holt KM, Hollander D. Acute gastric mucosal injury: pathogenesis and therapy. Annu Rev Med 1986; 37:107-124.
2. Kaunitz JD, Akiba Y. Duodenal carbonic anhydrase: mucosal protection, luminal chemosensing, and gastric acid disposal. Keio J Med 2006; 55:96-106. Summary of the latest thinking regarding the multiple roles of mucosal carbonic anhydrases.
3. Martin GR, Wallace JL. Gastrointestinal inflammation: a central component of mucosal defense and repair. Exp Biol Med (Maywood) 2006; 231:130-137. Excellent recent review addressing the role of inflammation in upper gastrointestinal injury.
4. Harada N, Okajima K, Uchiba M, Katsuragi T. Contribution of capsaicin-sensitive sensory neurons to stress-induced increases in gastric tissue levels of prostaglandins in rats. Am J Physiol Gastrointest Liver Physiol 2003; 285:G1214-G1224.
5. Shimozawa N, Okajima K, Harada N, et al. Contribution of sensory neurons to sex difference in the development of stress-induced gastric mucosal injury in mice. Gastroenterology 2006; 131:1826-1834. The authors test the hypothesis that the differences in the mucosal afferent nerve neuropeptide and nitric oxide pathways can explain the gender disparity observed with the production of rodent stress ulcers.
6. 2+ dependent and is induced by mechanical plasma membrane disruption, thus protecting the gastrointestinal tract from mechanical stress.
7. 2+-dependent signaling pathways and 5-HT4 receptors in mice. Am J Physiol Gastrointest Liver Physiol 2004; 286:G444-G451.
8. Kellum JM, Donowitz M, Cerel A, Wu J. Acid and isoproterenol cause serotonin release by acting on opposite surfaces of duodenal mucosa. J Surg Res 1984; 36:172-176.
9. + channels and cystic fibrosis transmembrane conductance regulator channels.
10. - secretion in mice. Am J Physiol Gastrointest Liver Physiol 2005; 288:G457-G465.
11. Lal S, Kirkup AJ, Brunsden AM, et al. Vagal afferent responses to fatty acids of different chain length in the rat. Am J Physiol Gastrointest Liver Physiol 2001; 281:G907-G915.
12. Mei N. Intestinal chemosensitivity. Physiol Rev 1985; 65:211-237.
13. Mei N. Vagal glucoreceptors in the small intestine of the cat. J Physiol 1978; 282:485-506.
14. Uneyama H, Niijima A, San GA, Torii K. Luminal amino acid sensing in the rat gastric mucosa. Am J Physiol Gastrointest Liver Physiol 2006; 291:G1163-G1170. Glutamate is 'tasted' by inducing nitric oxide and serotonin, which activates afferent fibers from the vagus nerve. This is a novel study in the nascent field of luminal chemosensing.
15. LePard KJ, Stephens RL Jr. Serotonin inhibits gastric acid secretion through a 5-hydroxytryptamine1-like receptor in the rat. J Pharmacol Exp Ther 1994; 270:1139-1144.
16. Tamura T, Sano I, Satoh M, et al. Pharmacological characterization of 5-hydroxytryptamine-induced motor activity (in vitro) in the guinea pig gastric antrum and corpus. Eur J Pharmacol 1996; 308:315-324.
17. Calatayud S, Barrachina D, Esplugues JV. Nitric oxide: relation to integrity, injury, and healing of the gastric mucosa. Microsc Res Tech 2001; 53:325-335.
18. Kosone T, Takagi H, Kakizaki S, et al. Integrative roles of transforming growth factor-alpha in the cytoprotection mechanisms of gastric mucosal injury. BMC Gastroenterol 2006; 6:22. In transgenic mice expressing TGF-α, mucosal gastric blood flow was maintained, iNOS was widely expressed, and COX-2 was consistently expressed before and after ethanol treatment, thus protecting the mucosa.
19. Dempsey PJ, Goldenring JR, Soroka CJ, et al. Possible role of transforming growth factor alpha in the pathogenesis of Menetrier's disease: supportive evidence form humans and transgenic mice. Gastroenterology 1992; 103:1950-1963.
20. Konturek SJ, Konturek PC, Brzozowski T. Melatonin in gastroprotection against stress-induced acute gastric lesions and in healing of chronic gastric ulcers. J Physiol Pharmacol 2006; 57 (Suppl 5):51-66. Melatonin is an endogenous antioxidant with antiinflammatory properties that is reported in this paper to have a novel role in the prevention of acute gastric damage and in enchaining mucosal repair.
21. Ganguly K, Kundu P, Banerjee A, et al. Hydrogen peroxide-mediated down-regulation of matrix metalloprotease-2 in indomethacin-induced acute gastric ulceration is blocked by melatonin and other antioxidants. Free Radic Biol Med 2006; 41:911-925. In inflammation, there is remodeling of connective tissues by MMPs. Antioxidants protect gastric mucosa by upregulating MMP-2 in indomethacin-induced injury.
22. Klupinska G, Wisniewska-Jarosinska M, Harasiuk A, et al. Nocturnal secretion of melatonin in patients with upper digestive tract disorders. J Physiol Pharmacol 2006; 57 (Suppl 5):41-50. Subjects with gastroesophageal reflux disease and recurrent duodenal ulcer had lower concentrations of melatonin as compared with healthy subjects.
23. Allen A, Hutton DA, Leonard AJ, et al. The role of mucus in the protection of the gastroduodenal mucosa. Scand J Gastroenterol Suppl 1986; 125:71-78.
24. Wong WM, Poulsom R, Wright NA. Trefoil peptides. Gut 1999; 44:890-895.
25. Suzuki K, Hayama M, Nakamura M, et al. Trefoil factor 2 in gland mucous cell mucin in the mucous gel covering normal or damaged gastric mucosa using the Mongolian gerbil model. Scand J Gastroenterol 2006; 41:1390-1397. TFF2 is found in gland mucous cell mucin, the surface mucus gel layer and in the mucoid cap overlying injured tissue. An interaction between TFF2 and mucin may augment mucosal defense.
26. Kurt-Jones EA, Cao L, Sandor F, et al. Trefoil family factor 2 is expressed in murine gastric and immune cells and controls both gastrointestinal inflammation and systemic immune responses. Infect Immun 2007; 75:471-480. TFF2 regulates inflammatory responses as seen by dysregulation of inflammation in TFF2 knockout mice.
27. Thim L, Madsen F, Poulsen SS. Effect of trefoil factors on the viscoelastic properties of mucus gels. Eur J Clin Invest 2002; 32:519-527.
28. Babyatsky MW, DeBeaumont M, Thim L, Podolsky DK. Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology 1996; 110:489-497.
29. Koitabashi A, Shimada T, Fujii Y, et al. Indometacin up-regulates TFF2 expression in gastric epithelial cells. Aliment Pharmacol Ther 2004; 20(Suppl 1):171-176.
30. Tu S, Chi AL, Lim S, et al. Gastrin regulates the TFF2 promoter through gastrin-responsive cis-acting elements and multiple signaling pathways. Am J Physiol Gastrointest Liver Physiol 2007; 292:G1726-G1737. Gastrin increases TFF2 expression via a protein kinase C, MEK1 and phosphatidylinositide-3- kinase-dependent pathway. This regulation of TFF2 by gastrin may be involved in mucosal defense.
31. Shimada T, Fujii Y, Koike T, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) regulates trefoil factor family 2 (TFF2) expression in gastric epithelial cells. Int J Biochem Cell Biol 2007; 39:626-637. PPAR-γ modulates gene transcription directly by binding to a peroxisome proliferator responsive element present on the TFF2 gene.
32. Takeuchi Y, Kitano S, Bandoh T, et al. Acceleration of gastric ulcer healing by omeprazole in portal hypertensive rats. Is its action mediated by gastrin release and the stimulation of epithelial proliferation? Eur Surg Res 2003; 35:75-80.
33. Li H, Helander HF. Hypergastrinemia increases proliferation of gastroduodenal epithelium during gastric ulcer healing in rats. Dig Dis Sci 1996; 41:40-48.
34. Corton JC, Anderson SP, Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 2000; 40:491-518.
35. 2S and its importance in regulating mucosal defense; pertinent to several papers cited in this review.
36. Fiorucci S, Antonelli E, Distrutti E, et al. Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology 2005; 129:1210-1224.
37. 2S inhibits leukocyte-endothelial adherence and decreases leukocyte infiltration, thus acting against inflammation.
38. Wallace JL, Caliendo G, Santagada V, et al. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 2007; 132:261-271. ATB-337 is a novel HS-NSAID that was found to have significantly less gastrointestinal injury than diclofenac. This may be due to decreased TNF-α expression and inhibition of leukocyte-endothelial interactions.
39. Lichtenberger LM. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem Pharmacol 2001; 61:631-637.
40. Darling RL, Romero JJ, Dial EJ, et al. The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice. Gastroenterology 2004; 127:94-104.
41. Petruzzelli M, Moschetta A, Renooij W, et al. Indomethacin enhances bile salt detergent activity: relevance for NSAIDs-induced gastrointestinal mucosal injury. Dig Dis Sci 2006; 51:766-774. Mucosal injury during NSAID therapy is likely due to its mixing with bile salts, which enhances the cytotoxicity of the bile. While indomethacin alone did not cause any hemolysis, indomethacin with bile salts induced hemolysis.
42. Petruzzelli M, Vacca M, Moschetta A, et al. Intestinal mucosal damage caused by nonsteroidal anti-inflammatory drugs: role of bile salts. Clin Biochem 2007; 40:503-510. A review of the role of bile salts in NSAID-induced mucosal damage.
43. Kiviluoto T, Paimela H, Mustonen H, Kivilaakso E. Exogenous surface-active phospholipid protects Necturus gastric mucosa against luminal acid and barrier-breaking agents. Gastroenterology 1991; 100:38-46.
44. Koyama T, Kawasaki S, Sakata H, et al. H. pylori and gastric phospholipids of peptic ulcer. Gastroenterology 1997; 112:1056-1057.
45. 2 mRNA in rat gastric mucosa and lung. Biochim Biophys Acta 1989; 1007:124-126.
46. Mansbach CM. Phospholipases: old enzymes with new meaning. Gastroenterology 1990; 98:1369-1382.
47. 2 in inflammatory and allergic diseases: not just enzymes. J Allergy Clin Immunol 2005; 116:1000-1006.
48. 2 inhibitor attenuates chemically induced gastroduodenal ulcers in rats. World J Gastroenterol 2006; 12:5798-5804. BPB protects from cysteamine and ethanol-induced ulcers by increasing gastric wall mucus, nonprotein sulfhydryls and myeloperoxidase.
49. Guardia T, Guzman JA, Pestchanker MJ, et al. Mucus synthesis and sulfhydryl groups in cytoprotection mediated by dehydroleucodine, a sesquiterpene lactone. J Nat Prod 1994; 57:507-509.
50. Salim AS. Sulphydryl-containing agents: a new approach to the problem of refractory peptic ulceration. Pharmacology 1992; 45:301-306.
51. Lichtenberger LM, Romero JJ, Dial EJ. Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Br J Pharmacol 2007; 150:913-919. Treatment with aspirin and a COX-2 inhibitor induced hemorrhagic lesions by decreasing gastric surface hydrophobicity, which was prevented or reduced by phosphatidylcholine-associated aspirin.
52. Lichtenberger LM, Zhou Y, Dial EJ, Raphael RM. NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. J Pharm Pharmacol 2006; 58:1421-1428. A review of the interaction between NSAIDs and membrane phospholipids finds that NSAIDs form pores in membranes that decrease stability and allow back-diffusion of acid, thus explaining their associated mucosal damage.
53. h2 cytokine-secreting profile. Clin Transplant 1999; 13:365-374.
54. Roviezzo F, Getting SJ, Paul-Clark MJ, et al. The annexin-1 knockout mouse: what it tells us about the inflammatory response. J Physiol Pharmacol 2002; 53:541-553.
55. Luo JC, Shin VY, Liu ES, et al. Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs. Eur J Pharmacol 2004; 485:275-281.
56. Luo JC, Chi CW, Lin HY, et al. Dexamethasone inhibits epidermal growth factor-stimulated gastric epithelial cell proliferation. J Pharmacol Exp Ther 2007; 320:687-694.
57. Brzozowski T, Konturek PC, Konturek SJ, et al. Effect of local application of growth factors on gastric ulcer healing and mucosal expression of cyclooxygenase-1 and -2. Digestion 2001; 64:15-29.
58. Tarnawski AS. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 2005; 50 (Suppl 1):S24-S33.
59. Yokota A, Taniguchi M, Takahira Y, et al. Dexamethasone damages the rat stomach but not small intestine during inhibition of COX-1. Dig Dis Sci 2007; 52:1452-1461. COX-1 inhibition with dexamethasone does not damage small intestine due to inhibition of iNOS.
60. Peskar BM, Ehrlich K, Egger T, Sattler W. Dexamethasone impairs the gastric mucosal integrity in rats treated with a cyclooxygenase-1 but not with a cyclooxygenase-2 inhibitor. Pharmacol 2006; 76:180-184. Up-regulation of COX-2 after COX-1 inhibition protects from gastric damage.
61. Tanaka A, Araki H, Hase S, et al. Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury. Aliment Pharmacol Ther 2002; 16 (Suppl 2):90-101.
62. Tanaka A, Hase S, Miyazawa T, Takeuchi K. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 2002; 300:754-761.
63. Tanaka A, Hase S, Miyazawa T, et al. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J Pharmacol Exp Ther 2002; 303:1248-1254.
64. Tanaka A, Kunikata T, Mizoguchi H, et al. Dual action of nitric oxide in pathogenesis of indomethacin-induced small intestinal ulceration in rats. J Physiol Pharmacol 1999; 50:405-417.
65. White WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension 2007; 49:408-418.
66. 14C]CS-706, to the arterial elastin of rats. Drug Metab Dispos 2006; 34:1417-1422. Cardiovascular events related to rofecoxib may be due in part to its binding to the elastin present in vessels. This binding, not seen with celecoxib or CS-706, may indicate that these coxibs are safer than is rofecoxib.
67. Moberly JB, Harris SI, Riff DS, et al. A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa. Dig Dis Sci 2007; 52:442-450. CS-706, a novel COX-2 inhibitor, causes significantly less mucosal injury than naproxen.
68. Rohatagi S, Kastrissios H, Gao Y, et al. Predictive population pharmacokinetic/ pharmacodynamic model for a novel COX-2 inhibitor. J Clin Pharmacol 2007; 47:358-370. Although CS-706 inhibits COX-1 and -2 at high doses, it is efficacious and inhibits COX-2 alone at lower doses, suggesting that it may have a favorable clinical profile.
69. Garcia Rodriguez LA, Barreales TL. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007; 132:498-506. Individual traditional nonselective NSAIDs and coxibs are compared in determining gastrointestinal safety. Although coxibs have slightly reduced risk for upper gastrointestinal complications relative to nonselective NSAIDs, this effect is negated by aspirin. Ibuprofen, a nonselective NSAID, has a similar safety profile to coxibs, despite vastly reduced cost.
70. Lanas A, Baron JA, Sandler RS, et al. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology 2007; 132:490-497. Patients with a history of colorectal adenomas were treated with rofecoxib over 3 years. Patients experienced significantly higher upper gastrointestinal complications with long-term rofecoxib treatment than with placebo treatment.